Prostate Cancer - Results from #28900

When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy? - Abstract February 9, 2011

Relationship between prostate-specific antigen and obesity in prostate cancer screening: Analysis of a large cohort in Japan - Abstract February 9, 2011

Exosomes as biomarker treasure chests for prostate cancer - Abstract February 9, 2011

Dose escalation improves cancer-related events at 10 years for intermediate- and high-risk prostate cancer patients treated with hypofractionated high-dose-rate boost and external beam radiotherapy - Abstract February 9, 2011

Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer - Abstract February 9, 2011

PSA density lower cutoff value as a tool to exclude pathologic upstaging in initially diagnosed unilateral prostate cancer: Impact on hemiablative focal therapy - Abstract February 9, 2011

Dutasteride not a cost-effective way to prevent prostate cancer in some February 9, 2011

Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study - Abstract February 8, 2011

Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid - Abstract February 8, 2011

5α-reductase type 3 expression in human benign and malignant tissues: A comparative analysis during prostate cancer progression - Abstract February 8, 2011

Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer - Abstract February 8, 2011

Endothelial progenitor cells and circulating endothelial cells in early prostate cancer: A comparison with plasma vascular markers - Abstract February 8, 2011

Vitamin D deficiency promotes prostate cancer growth in bone - Abstract February 8, 2011

Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: A phase 2 study of the Department of Defense prostate cancer clinical trials consortium - Abstract February 8, 2011

33% radius evaluation to assess bone mineral density in prostate cancer patients - Abstract February 8, 2011

Use and evaluation of a CD-ROM-based decision aid for prostate cancer treatment decisions - Abstract February 7, 2011

Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer - Abstract February 7, 2011

A review of African American-white differences in risk factors for cancer: Prostate cancer - Abstract February 7, 2011

Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer - Abstract February 7, 2011

Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: Technique, early toxicity, and PSA response - Abstract February 7, 2011

Page 1446 of 1449